This segment focuses on the development and commercialization of advanced molecular diagnostic tests for urologic cancers, primarily prostate and bladder cancer. Research and development activities include biomarker discovery, assay development, and clinical validation of tests like ConfirmMDx and SelectMDx. The core technology utilizes epigenetic and molecular analysis to assess cancer risk, guide treatment decisions, and predict patient outcomes. The tests provide physicians with critical information for diagnosis, prognosis, and personalized therapy selection. This segment aims to improve patient outcomes by enabling earlier and more accurate cancer detection, reducing unnecessary biopsies, and optimizing treatment strategies. MDxHealth's market positioning is strengthened by its focus on precision diagnostics and its collaborations with leading healthcare providers. Future opportunities include expanding the test portfolio to cover other urologic cancers and developing companion diagnostics for targeted therapies. Regulatory and clinical aspects involve obtaining necessary approvals and demonstrating clinical utility through rigorous studies. Partnerships with healthcare providers and pharmaceutical companies are crucial for market access and commercialization.